Skip to content

Effect of Ultrasound-Guided Liposomal Bupivacaine Posterior Rectus Sheath Nerve Block for Postoperative Analgesia in Single-Port Laparoscopic Gynecological Surgery: A Multicenter, Prospective, Randomized Controlled Clinical Trial

Effect of Ultrasound-Guided Liposomal Bupivacaine Posterior Rectus Sheath Nerve Block for Postoperative Analgesia in Single-Port Laparoscopic Gynecological Surgery: A Multicenter, Prospective, Randomized Controlled Clinical Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102369
Enrollment
Unknown
Registered
2025-05-13
Start date
2025-06-08
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pain after surgery for female reproductive system diseases

Interventions

Total venous patient-controlled analgesia group:In the total intravenous patient-controlled analgesia group, no puncture injection operation was performed at the position of the rectus abdominis sheat
Bupivacaine liposomal sheath block of rectus abdominis combined with total intravenous patient-controlled analgesia:Before the operation began, ultrasound-guided bilateral posterior sheath block of th

Sponsors

West China Tianfu Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1)Patients scheduled to undergo single-port laparoscopic gynecologic surgery 2)Aged >= 14 years 3)ASA I-III;

Exclusion criteria

Exclusion criteria: 1) Contraindications to nerve block (e.g., infection at the puncture site, coagulopathy); 2) History of allergy to bupivacaine or liposomal drugs; 3) Severe hepatic or renal dysfunction; 4) History of chronic pain or long-term opioid use; 5) Patients unable to communicate or comply with follow-up 6) Refusal to use the patient-controlled analgesia (PCA) pump; 7) Pregnant or lactating women; 8) Concurrent participation in other clinical trials; 9) Deemed unsuitable for inclusion by the surgeon or anesthesiologist.

Design outcomes

Primary

MeasureTime frame
Area under the 72-hour pain score curve;

Secondary

MeasureTime frame
The resting and exercise NRS scores of the patients at 2h, 6 h, 12 h, 24 h, 48 h and 72h after the operation;The total number of compressions and the total dosage of analgesic pump drugs at 24, 48 and 72 hours after the operation;Types and frequency of postoperative remedial analgesic drugs: The total amount of opioid drugs used in the PACU and ward within 3 days after the operation, as well as the usage of other remedial analgesic drugs; Including the types and frequencies of remedial drugs;The time of getting out of bed for the first time after the operation;The time of the first exhaust from the anus of the postoperative patient;;The Qor-15 scores of recovery quality at 24 and 72 hours after the operation;Length of hospital stay;Hospitalization expenses;Adverse events during hospitalization: Intraoperative adverse events (hypertension (blood pressure > 30% of baseline), hypotension (blood pressure 100 beats/minute), etc.), postoperative adverse events: nausea, vomiting, dizziness, urinary retention, etc;

Countries

China

Contacts

Public Contactxiaoqiangli

West China tianfu Hospital of Sichuan University

39006900@qq.com+86 189 8060 1475

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026